Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2051
Friedman Industries
FRD
$331M
| $2.52M | ﹤0.01% |
499,619
+9,399
| +2% | +$43.3K |
|
2052
MBIA
MBI
$264M
| $2.52M | ﹤0.01% |
347,492
-438,300
| -56% | -$3.18M |
|
2053
Envela
ELA
$416M
| $2.52M | ﹤0.01% |
412,717
+192,623
| +88% | +$704K |
|
|
GPL
2054
DELISTED
Great Panther Mining Limited
GPL
| $2.51M | ﹤0.01% |
502,337
+154,360
| +44% | +$683K |
|
|
IO
2055
DELISTED
ION Geophysical Corporation
IO
| $2.51M | ﹤0.01% |
1,073,367
-24,030
| -2% | -$52.5K |
|
|
SA
2056
Seabridge Gold
SA
$3.61B
| $2.51M | ﹤0.01% |
+143,162
| New | +$2.02M |
|
2057
FMC
FMC
$1.27B
| $2.51M | ﹤0.01% |
+25,200
| New | +$2.33M |
|
|
LBC
2058
DELISTED
Luther Burbank Corporation Common Stock
LBC
| $2.5M | ﹤0.01% |
250,368
-3,100
| -1% | -$29.9K |
|
|
CRHM
2059
DELISTED
CRH Medical Corporation
CRHM
| $2.5M | ﹤0.01% |
1,205,485
-348,500
| -22% | -$704K |
|
2060
Peoples Financial Services
PFIS
$714M
| $2.5M | ﹤0.01% |
65,381
-14,500
| -18% | -$503K |
|
2061
Arlo Technologies
ARLO
$1.54B
| $2.5M | ﹤0.01% |
967,230
+287,630
| +42% | +$695K |
|
|
LEJU
2062
DELISTED
Leju Holdings Limited American Depositary Shares, each representing ten (10) Ordinary Shares
LEJU
| $2.5M | ﹤0.01% |
136,315
+6,719
| +5% | +$118K |
|
|
PRNB
2063
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $2.49M | ﹤0.01% |
41,700
-92,400
| -69% | -$5.71M |
|
2064
Navient
NAVI
$860M
| $2.49M | ﹤0.01% |
+354,300
| New | +$2.64M |
|
2065
DLH Holdings
DLHC
$67.5M
| $2.49M | ﹤0.01% |
339,168
+53,841
| +19% | +$337K |
|
2066
Atlantic Union Bankshares
AUB
$6.12B
| $2.49M | ﹤0.01% |
107,394
-182,008
| -63% | -$4.1M |
|
|
OPTN
2067
DELISTED
OptiNose
OPTN
| $2.49M | ﹤0.01% |
22,280
+7,387
| +50% | +$526K |
|
2068
Arcos Dorados Holdings
ARCO
$1.67B
| $2.48M | ﹤0.01% |
609,027
+30,335
| +5% | +$113K |
|
2069
Coca-Cola Consolidated
COKE
$12.6B
| $2.48M | ﹤0.01% |
108,270
+89,270
| +470% | +$2.09M |
|
2070
Cue Biopharma
CUE
$144M
| $2.48M | ﹤0.01% |
3,367
+687
| +26% | +$498K |
|
|
TSC
2071
DELISTED
TriState Capital Holdings, Inc.
TSC
| $2.47M | ﹤0.01% |
157,100
-184,523
| -54% | -$2.51M |
|
2072
Citizens
CIA
$201M
| $2.47M | ﹤0.01% |
411,800
-45,800
| -10% | -$263K |
|
|
SRGA
2073
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $2.47M | ﹤0.01% |
25,859
-8,424
| -25% | -$628K |
|
2074
Galicia Financial Group
GGAL
$6.97B
| $2.46M | ﹤0.01% |
+253,700
| New | +$2.17M |
|
|
SCPH
2075
DELISTED
scPharmaceuticals
SCPH
| $2.46M | ﹤0.01% |
333,686
+141,200
| +73% | +$1.24M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.